These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents. Spinler SA Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808 [TBL] [Abstract][Full Text] [Related]
26. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818 [TBL] [Abstract][Full Text] [Related]
27. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
28. Status of drug-eluting coronary stents. Chodosh A; Korr KS; Burtt D Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106 [TBL] [Abstract][Full Text] [Related]
31. Medical therapy versus percutaneous coronary intervention for patients with stable coronary artery disease. Arbab-Zadeh A J Am Coll Cardiol; 2009 Feb; 53(6):528-9; author reply 529. PubMed ID: 19195616 [No Abstract] [Full Text] [Related]
32. The efficacy of aspirin in peripheral arterial disease: an unresolved question. Hiatt WR; Krantz MJ J Mal Vasc; 2007 Apr; 32(2):71-2. PubMed ID: 17382504 [No Abstract] [Full Text] [Related]
33. Endovascular treatment of peripheral vascular disease. Allaqaband S; Kirvaitis R; Jan F; Bajwa T Curr Probl Cardiol; 2009 Sep; 34(9):359-476. PubMed ID: 19664498 [TBL] [Abstract][Full Text] [Related]
34. Nonresponders to clopidogrel therapy among Indian patients undergoing elective/adhoc angioplasty. Thomson VS; John B; Pati PK; George OK; George PV; Jose J Indian Heart J; 2008; 60(6):543-7. PubMed ID: 19276493 [TBL] [Abstract][Full Text] [Related]
35. Optimal medical management of peripheral arterial disease. Paraskevas KI; Hamilton G; Mikhailidis DP; Liapis CD Vasc Endovascular Surg; 2007; 41(1):87. PubMed ID: 17277251 [No Abstract] [Full Text] [Related]
36. Current concepts in antiplatelet therapy for cardiovascular disease. Martinez A JAAPA; 2004 Mar; 17(3):16-20, 23-4; quiz 51-2. PubMed ID: 15314880 [No Abstract] [Full Text] [Related]
37. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Bhatt DL Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708 [TBL] [Abstract][Full Text] [Related]
38. Tissue engineering therapy for cardiovascular diseases. Tiwari A; Hamilton G; Seifalian AM Circ Res; 2003 Jul; 93(2):e1. PubMed ID: 12881476 [No Abstract] [Full Text] [Related]
39. An interesting and provocative issue to close out the 10th volume of CRM. Waksman R Cardiovasc Revasc Med; 2009; 10(4):215. PubMed ID: 19815166 [No Abstract] [Full Text] [Related]
40. Is the glass 97% full, or 3% empty? Reinfarction and stent thrombosis after STEMI. Morrison DA Catheter Cardiovasc Interv; 2009 Apr; 73(5):635-6. PubMed ID: 19309703 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]